Cover Image
市場調查報告書

日本製藥公司的未來展望:針對公認學名藥 (AG),生技仿製藥,海外策略值得注意的1年

Japan Pharma Outlook 2015: 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

出版商 MP Advisors 商品編碼 295953
出版日期 內容資訊 英文 153 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本製藥公司的未來展望:針對公認學名藥 (AG),生技仿製藥,海外策略值得注意的1年 Japan Pharma Outlook 2015: 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives
出版日期: 2015年01月27日 內容資訊: 英文 153 Pages
簡介

2014年4月的藥價改定造成了對創新企業、學名藥企業雙方都帶來打擊的結果,無論何種企業都為了因應新法規而必須重新擬定國內市場策略(以及海外市場策略)。創新企業方面擁有活用AG (Authorized Generics:公認學名醫藥品)制度來對抗學名藥企業這樣的選擇。日本雖然AG的型式及法規尚未確立,但 BlopressのAG前些時日推出,對此學名藥企業展現出與之對抗的動向,而漸漸拓展出日本AG普及之道。創新企業方面則以腫瘤,其次為再生醫療及孤兒藥為研究開發(R&D) 活動的中心。

本報告提供日本的生物醫藥品市場相關之詳細調查,彙整主要13家企業 (首發藥/學名藥的專業企業及兼營企業) 之開發中產品和成長推動因素,策略發展資訊 (AG,生技仿製藥,向海外發展等) 資訊,為您概述為以下內容。

企業分析

  • Astellas Pharma Inc.:Xtandi (前列腺癌症用)和Isavuconazole在美國取得認證,得到下一步革新 (Roxadustat,CMV疫苗,ASP8273)的基礎
  • 中外製藥:乳癌的專利權/特許經銷代理人
  • 第一三共:隨著Edoxaban通過認證,及Ranbaxy的Sun Pharma的轉讓而提高了業績
  • 大日本住友製藥:Latuda的成長成了推進再生醫療·細胞療法的技術創新的關鍵
  • Eisai:只求研究開發(R&D)的成功
  • Kyowa Hakko Kirin:Poteligeo和IO Therapy的組合臨床實驗,關係到今後發展之道
  • Meiji Seika Pharma:為促進成長而強化中樞神經系統(CNS)部門與GX融合策略
  • 田邊三菱製藥:強化海外產業的未來性
  • 鹽野義製藥:Tivicay和Triumeq -下一步的革新階段
  • 信必優製藥:Treakisym的適用範圍擴大引人注目
  • 武田藥品工業:新產品(Entyvio,Takecab,Brintellix的)上市,是否將成為下一步成長循環的線索

日本的學名藥企業

  • Nippon Chemipher:不受新藥價左右的體制是其優勢
  • 澤井製藥:因應困難時期
  • 東和藥品:隨著藥價修改之經營困難

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 4481

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations. For the innovators - testing Authorized Generics (AGs) phenomenon for protecting their long-listed sales against generic could be one of new choice in Japan. The format and regulations for AG's are still not clear in Japan, however with the largest Japanese product Blopress AG's launched recently and generic companies in queue to compete with their generic versions will make the things lucid for the fate of AG's in Japan.

For most of the generic companies focusing on reducing manufacturing costs, and for many of them to venture in biosimilars space as a new growth avenue would be focus. The trends suggest that Japanese companies may need to set up or alliance with companies overseas for manufacturing. In this note of Outlook-15, we look deeper into these trends to anticipate likely near term changes of Japanese pharma industry.

In innovation space, after Oncology, regenerative medicine and Orphan disease are the areas where Japanese innovator companies are focusing its R & D efforts. While from late stage pipeline/new launch, Edoxaban, Lenvatinib, Entyvio, Brintellix, and Ixazomib are the few important NCEs, uptake of which will decide Japanese Innovator growth in Global market. In this report- We analyzed pipeline, strategies and key growth drivers of 13 major Japanese biopharma companies (Pure play innovators/ Innovators+ Generics/Pure play generics) and detailed our view on these growth drivers along with their interest for inlicensing external innovation from the globe for increasing R&D productivity. 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

Company Analysis:

Astellas - Xtandi uptake in Pre-chemo PC, Isavuconazole US approval & Uptake will provide cushion to Next batch of innovation (Roxadustat, CMV vaccine, ASP8273)!

  • Xtandi- Xtandi's early stage clinical data in HER2 positive, HR+ve, AR +ve Breast cancer and Data from TERRAIN/STRIVE study in early PC will drive Xtandi momentum in 2015, while PhIII data read out of ARN-509 from SPARTAN study is the key near term threat
  • Isavuconazole: Our view on US approval and Uptake
  • Myrbetriq: Myrbetriq uptake in OAB market - a blockbuster potential likely- EB178 (FDC/combo of Solifenacin+ Mirabegron) combination - Next Batch of Innovation
  • Roxadustat- Can change the current treatment paradigm mainly in CKD-NDPatients- AKB-6548 is the key competitor
    • Key advantage over current EPO
    • Biosimilar EPO is not a threat
    • Pipeline HIF inhibitors and clinical data comparison
  • ASP-8273 (Ph 1, Irreversible mutant selective EGFR inhibitor)
  • Evolocumab
  • Table 1: Deals done by Astellas in 2013, 2014
  • Table 2: Pipeline Early stage Androgen Receptor antagonist
  • Table 3: Competitive landscape for Antifungals
  • Table 4: Competitive landscapes for OAB drugs
  • Table 5: Pipeline HIF alpha stabilizer- AKEBIA AKB-6548 is closest competitor
  • Table 6: Competitive landscape- Anti PCSK9 MAB- ALIROCUMAB vs. EVOLOCUMAB
  • Chart: 1, 2 - Current and Future use of anti androgens in treatment of Prostate Cancer Chugai - Alectinib, ACE910 Global Success - Next Growth Driver!

Chugai's - Breast Cancer Franchisee: Breast Cancer Franchise-

  • Perjeta will be the key growth driver for the franchisee-not Kadcyla -
  • In long term, Perjeta + Herceptin + Chemo will be the standard of care vs. currently Herceptin + chemo. Kadcyla will cater 2nd line market, while data from APHINITY trial in 2016 will decide Perjeta + Herceptin use for adjuvant setting in Breast cancer
  • Failure of MARIANNE Study further increases threat of Herceptin biosimilar
    • Chugai's NSCLC franchisee:
  • MPDL3280A (anti-PDL1 mAB, PhIII, NSCLC, Melanoma) - It is in PhIII in Japan and for NSCLC indication- Nivolumab is the closest competitor.
    • April 2014 price cut to Long listed products resulted in sales decline of Suvenyl, Sigmart and Alfarol ....
    • MPDL3280A - Anti PD1 from Roche- competitive landscape and status in Japan
  • Table 1: Deals Done By Chugai Pharma in 2013-2014
  • Table 2: Ongoing Important Clinical Studies of Kadcyla in Late Stage Her 2 Positive Cancers
  • Table 3: Actemra - Ongoing Global Trials

Daiichi Sankyo -Edoxaban uptake + Ranbaxy/Sun Closure will provide Momentum in 2015!

  • Ranbaxy +Sun= Sun = 9% equity stake in New Sun- Exit or hold???-
  • Vision 2017 Revision is expected around FY03/15 results:
  • Edoxaban: A blockbuster potential likely despite restricted US launch and will be 4th Entrant in NOAC market
  • Acquisition of Ambit bioscience
  • Quizaritinib
  • Other Assets from Ambit
  • Other Assets in Pipeline- CL 108 and Etanercept biosimilar
  • JP domestic market - Long listed products sales decline.....
  • Daiichi Sankyo Espha (DSE) - New pricing policy make difficult road ahead
  • Table 1: Edoxaban - Possible Scenario Analysis and Peak Sales Estimate
  • Table 2: % Patients Crcl<95% In Key Pivotal Studies Of Noac In Nvaf
  • Table 3: Launched Noac- Efficacy And Safety Comparision - In Renally Imparied Patients
  • Table 4: Launched Noac- Ww Reported Sales
  • Table 5: Competitive Landscape - Select Late And Mid Stage Drug Targeting Aml
  • Table 6: Select Jak 2/1 Inhibitors: Mid- To Late-Stage Pipeline
  • Annexure 1: 5-Year Business Plan: Numerical Targets For Fy2017
  • Annexure 2: Core Strategies Of 5-Year Business Plan
  • Annexure-3: New Generation Oral Anticoagulants - Market Dynamics

Dainippon Sumitomo Pharma - Latuda growth is the Key to support Regenerative/Cell therapy Innovation!

  • BBI-608 - Post failure in PhIII CRC (Colorectal cancer) study, focus now shifts to PhIII clinical data
    • Pipeline CSC Inhibitors
  • BBI-503- Clinical data from PhI/II study in 2015 will decide its future potential-BBI-503
  • Regenerative medicine/Cell therapy medicine - A long way to go!!!-SB623
  • Other Pipeline candidates:
    • EPI-743
    • AS-3201 (Ranirestat)
    • DSP-1747
    • Dasotraline
  • Table 1: Pipeline Of Drugs Targeting Cancer Stem Cell
  • Table 2: Pipeline Of Boston Biomedical
  • Table 3: Psychiatrists See High Unmet Need
  • Table 4: Latuda Swot Analysis
  • Table 5: Dainippon Sumitomo-Key Pipeline Candidates- Japan
  • Table 6: Dainippon Sumitomo-Key Pipeline Candidates- Us
  • Table 7: Deals Done By Dainippon In 2013-2014
  • Chart 1: Atypical antipsychotics market

Eisai - Success in R&D is the Only Hope!

  • LENVATINIB
  • Thyroid cancer
  • Hepatocellular carcinoma
  • Lung Cancer
    • Table 1: Sales outlook for major lung cancer drugs vs. Lenvatinib expectation
  • Halaven - Eisai's Flagship Product After Aricept and Aciphex
    • Table 2: Indications Prospects For Halaven
  • Fycompa to maintain presences into CNS space
  • E2006 is another candidate strengthening base of CNS franchise
  • Annexure 1; EISAI R&D Pipeline (Ph II and III Only)

Kyowa Hakko Kirin - Poteligeo Combination Trial With IO Therapy Will Drive The Story

  • KHK's Potelligent technology
  • Biosimilar JV

Our view on its global late stage pipeline candidates

  • KW-0761
  • KW-6002
  • KRN-23
  • MEDI-563/Benralizumab/KHK4563
  • Archimedes acquisition Strengthen Prostakan Product portfolio + EU presence
  • Newly launched products in Domestic Market (Japan) Poteligeo, Nouriast, Onglyza - Very slow
  • uptake does not allow KHK to withstand pricing pressure /biosimilar competition in domestic
  • market - G-Lasta may change the picture
  • Table 1: Competitive Landscape Of Biologics In Severe Asthma
  • Table 2: Parkinson's disease competitive landscape of recently launched PD Drugs in Japan
  • Table 3: Global Pipeline And Our Comments
  • Table 4: Deals Done By Khk In 2013-2014
  • Table 5: Potelligent Technology

Meiji Seika- : Strengthening CNS Foothold & Gx Fusion Strategy to Drive Growth

  • The core focus on antidepressant market is going to strengthen further:
  • Medreich Acquisition - a bold step to venture into overseas markets
  • Success in Generic business likely to continue
  • Table 1: Pharma contribution on sales
  • Table 2: High Profitability of Pharma Segment
  • Table 3: R & D pipeline
  • Table 4: Meiji Seika overseas R & D activity

Mitsubishi Tanabe - Overseas Efforts to be intensified in Coming Years!

  • Growth drivers vs. long listed exposure
  • Our view on MT's acquisition strategy
  • Remicade: biosimilars are unlikely to generate massive loss in near term
  • Invokana- to play important role in Japan SGLT-2 inhibitor market
    • Invokana US prescription vs. newly launched products in type 2 diabetes space
  • Gilenya: Gilenya sales well on track, no impact of negative data from PPMS
  • Our view on Gilenya growth going forward & upcoming competition
  • Key reasons why Gilenya will continue to Maintain its market share in the new competitive landscape
  • Venture into Vaccine Business to unfold soon
  • Table 1:Clinical data comparison of CT-P13 (Celtrion/NK Remicade biosimilar) vs. INX. In RA (54 week, PLANETRA study) in EU study
  • Table 2: Top Ten Most Expensive Drugs Procured By Tokyo Medical Hospital
  • Table 3: SGLT -2 Inhibitors And Dppiv Players In Japan

Shionogi - Tivicay + Triumeq- Cushion for Shionogi's Next Batch of Innovation!

  • Tivicay- Tivicay (Dolutegravir) best in class profile has already set the stage for Triumeq use in first line setting, and helps Triumeq to take the market share from Atripla/ Stribild, Post 2018, FDC with Truvada is a free call option
    • Pipeline HIV drugs competing with Triumeq- No near term threat- TAF- Stribild has its own disadvantage
  • Shionogi- Late stage pipeline analysis of the global candidates (Table 5)
    • S-297995
    • S-888711 (Lusutrombopag)
  • Shionogi- Early stage pipeline analysis
    • S-222611
    • S-010887
  • Shionogi- Japan- late stage pipeline analysis (Table 7)
    • S-556971
    • S-877489 9
  • Chart 1: Tivicay Prescription Trend vs. Isentress VS. Stribild
  • Chart 2: TIVICAY VS. ISENTRESS VS. STRIBILD- MARKET SHARE
  • Chart 3: Current HIV treatment paradigm
  • Table 1: Single Trial Data- Triumeq vs. Atripla
  • Table 2: Dolutegravir - Phiii Trials
  • Table 3: Treatment Of Thrombocytopenia - Recently Approved Drugs + Late Stage Pipeline
  • Table 4: Global Clinical Data Comparison Of Late Stage Oral Tpo Mimetics For Treatment OF Thrombocytopenia Associated With Chronic Liver Disease
  • Table 5: Shionogi- Late Stage Pipeline Analysis Of Global Candidates
  • Table 6: Shionogi- Early Stage Pipeline Analysis - Out Licensing Opportunities
  • Table 7: Shionogi- Early Stage Pipeline Analysis - Out Licensing Opportunities
  • Table 8: Deals Done By Shionogi In 2013-2014

Symbio Pharmaceuticals: All Eyes Are On Label Expansion Of Treakisym

  • Rigosertib - Catering Niche despite Negative ONTIME data- Ph II data read out by
  • YE2014/1H2015 will decide First line potential
    • In 2nd-line Higher Risk MDS patients (IV Rigosertib)
    • In 1st line lower risk MDS pts (Oral Rigosertib)
  • TREAKISYM
    • CLL
    • Front line NHL
    • RR aggressive NHL
    • Upcoming Milestones
  • Chart 1: Symbio- Pipeline
  • Table 1: RR/2nd line HR MDS- Select late-to mid stage pipeline

Takeda -Will the New Launches (Entyvio, Takecab, and Brintellix) Set The Stage For Next Growth Cycle???

  • Key milestones to watch for in 2015 are
  • EU portfolio becoming strong post ENTYVIO and Natura alpha launch - Nycomed's strong GI market presence will boost this franchise
  • Entyvio (Vedolizumab/MLN0002, approved US/EU, vedolizumab, α4β7 integrin inhibitor, Ulcerative colitis / Crohn's disease): Strong uptake confirms differentiated profile- blockbuster potential likely
  • Competition from Pipeline drugs:
  • Brintellix (Vortioxetine) - Cognition data will differentiate Brintellix in genericized depression market-
    • Vortioxetine vs. Currently Available Drugs
  • MLN-9708 (PhIII, Multiple Myeloma) interim PhIII data in RRMM in combination with Revlimid in 2015 will decide its potential in crowded Multiple Myeloma market:
  • Expected competition to Velcade in Second/third line setting and upcoming milestones before patent expiry (2017)
  • Table 1: Deals Done By Takeda In 2013-2014
  • Table 2: Key Late Stage Pipeline Global Candidates- Takeda
  • Table 3: Pipeline Leukocyte Traffic Inhibitor (Integrin Inhibitor)
  • Chart 1: Mln9708 -Trial Design Of Tourmaline-Mm1 - Rrmm
  • Table 4: competitive landscape -mln 0002/vedolizumab vs. marketed mab in ulcerative colitis
  • Table 5: Takeda Competitive Landscape mln 0002/vedolizumab vs. marketed mab in crohn's disease
  • Table 6: Takeda Mln 0002/Vedolizumab Clinical Trial Program
  • Table 7: Vortioxetine - Major Depressive Disorder
  • Table 8: Vortioxetine - Major Depressive Disorder - Drugs Discontinued In The Recent Past
  • Table 9: Vortioxetine - Major Depressive Disorder - Competitive Landscape
  • Table 10: Data Comparison - Newly Diagnosed Multiple Myeloma (Ndmm)
  • Chart 2: MLN-9708 Trial design
  • Chart 3: Reported adverse events in clinical trials- MLN9708
  • Table 11: Data Comparison - Relapsed And Refractory Multiple Myeloma (Rrmm)
  • Table 12: Data Comparison - Relapsed And Refractory Multiple Myeloma (Rrmm) -

JAPAN GENERICS:

Nippon Chemiphar - Less Vulnerability to New Pricing System is Advantageous!

  • Relatively Modest Margins Profile Compared to Peers
  • Impact of April 14 NHI price revision
  • A balanced portfolio provides flexibility in adopting favorable market strategies:
  • Table 1: Nippon Chemiphar Sales break up
  • Annexure 1- Key Features of New NHI Pricing System

Sawai - Poised Well To Sail Through Tough Times!

  • Gradually improving wholesaler base is advantageous
  • Table 1: Gradually Improving Wholesaler Base

Primary Care Focused Product Mix- Not Highly Profitable yet less Risky

  • Table 2: Balanced Primary Care Products-Mix
  • Table 3: Better Performance by New products
  • Table 4: Value To/Of Products Going Off Patent In Next 5 Years
  • Table 5: Newly Listed Products In 2014
  • Figure 1: Sawai- Medium to long term vision

Towa - Tough Time In Adapting To New Pricing Regulations!

  • Need of decreasing dependence on direct sales channel under changed scenarios:
  • A solid foundation of organic growth is in place through years of constant Capex and R&D investments
  • GP Market Focus is Moving to DP Markets; HP Needs Improvement
  • Japan Generic Industry Outlook
  • Table 1: Direct Sales On Rise
  • Chart 1: Constantly Increasing Capex
  • Table 2: Key Launches Of 2014
  • Table 3: Steady Performance Of Key Products
  • Table 4: GP Market Focus Switching To DP Market
Back to Top